For the final 10% of cystic fibrosis patients, the breakthrough still hasn't come

The fact that 10% of cystic fibrosis patients cannot benefit from current breakthrough drugs highlights a significant gap in treatment options for this group. Emily's Entourage, a funding organization, is taking a proactive approach by investing in research to find new treatments for these patients. This effort is crucial as it brings hope to those who have been left behind by existing therapies, and it also underscores the importance of continued innovation in the field of cystic fibrosis research.

The funding of research by Emily's Entourage matters because it demonstrates the commitment of organizations to addressing unmet medical needs. In the context of the pharmaceutical industry, it is not uncommon for a subset of patients to not respond to or benefit from groundbreaking treatments. The existence of this 10% of cystic fibrosis patients who do not benefit from current drugs serves as a reminder that there is still much work to be done in finding effective treatments for all patients. By supporting research, Emily's Entourage is helping to drive progress and potentially pave the way for new therapies.

As the research funded by Emily's Entourage progresses, it will be important to watch for any breakthroughs or advancements that could lead to new treatment options for the 10% of cystic fibrosis patients who currently have limited choices. The success of this research could also have implications for the broader cystic fibrosis community, potentially leading to a greater understanding of the disease and the development of more targeted therapies. Additionally, the impact of Emily's Entourage's funding efforts could serve as a model for other organizations seeking to address unmet medical needs in their respective fields.

Originally reported by cnbc.com. FundNews adds analysis for finance & markets readers.